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Summan A randomised clinical trial has been conducted to compare adjuvant tamoxifen. 20 mg daily. with
tamoxifen and prednisolone. 7.5 mg daily. in post-menopausal women with operable breast cancer. There were
254 evaluable patients. of whom 128 were given tamoxifen alone and 126 received tamoxifen and prednisolone.
After a median follow-up of 48 months there was no significant difference in relapse-free or overall survival of
the two groups. Furthermore, with survival slightly favouring tamoxifen. confidence intervals on the hazard
ratio established that a difference in favour of tamoxifen plus prednisolone of even 5% at 5 years was very
unlikely (P<0.02) Thus. despite the relatively small number of patients in this trial. the data clearly establish
that prednisolone is not of value as an additional adjuvant agent.
As a result of the overview of adjuvant trials for patients
with early beast cancer there is now a general agreement that
post-menopausal women benefit from adjuvant tamoxifen
(EBCTG. 1992). Overall. tamoxifen produces a 25% reduc-
tion in the annual odds of relapse and a 17% reduction in
the annual odds of death from breast cancer. A reduction in
mortality was first demonstrated by the Nolvadex Adjuvant
Trial Organisation (NATO. 1988).
The benefits of tamoxifen are seen in patients with either
node-positive of node-negative disease. The main benefit is
seen in those with oestrogen receptor (ER)-positive tumours,
but there is a small effect in those with ER-negative cancers
(NATO. 1988). Thus, most post-menopausal patients are
now being given tamoxifen.
In order to try and increase the benefits of tamoxifen. we
have conducted an adjuvant trial comparing tamoxifen alone
against tamoxifen and prednisolone. The rationale for the
study arose from a trial which had shown that prednisolone
is of value in women with advanced breast cancer (Rubens et
al.. 1988). In this trial, which included 220 patients.
premenopausal women received ovarian irradiation and post-
menopausal women were given tamoxifen. They were ran-
domised to have primary endocrine therapy either alone or
with prednisolone 5 mg twice daily. Among those given
primary endocrine therapy alone, a complete or partial res-
ponse was seen in 30% compared with 49% for those given
primary endocrine therapy and prednisolone. The median
duration of response was increased from 9 to 14 months by
prednisolone and the median time to disease progression
increased from 5 to 9 months.
Additional evidence that prednisolone was beneficial as an
adjuvant treatment was provided by the Princess Margaret
Hospital trial (Meakin et al., 1979). A group of 224
premenopausal women aged over 45 were given post-
operative radiotherapy following mastectomy. They were
randomised to no further treatment (66), ovarian irradiation
(78) or ovarian irradiation and prednisolone 7.5 mg daily
(80). After 10 years of follow-up the relapse-free and overall
survival of the group given prednisolone was significantly
better than that of the other two groups.
These data suggested that the addition of prednisolone
might be beneficial. This trial was designed to test tamoxifen
20 mg against tamoxifen 20 mg and prednisolone 7.5 mg and
to determine the side-effects of these treatments.
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Materials and methods
To be eligible for the trial patients had to be post-meno-
pausal (no periods for the previous 6 months) or aged over
50 if a hysterectomy had been performed with preservation
of at least one ovary. The upper age limit for entry was 70
years. Patients with hypertension. diabetes or a peptic ulcer
were not eligible since prednisolone would be contraindicat-
ed. Those already taking steroids were excluded.
A total of 370 women were entered into the trial, 269 from
Guy's and 101 from Withington Hospital. The characteristics
of the patients from the two hospitals are given in Table I.
Overall, 29 patients were deemed eligible and were therefore
randomised in error, of whom 20 were premenopausal. Other
reasons for ineligibility were prior use of prednisolone (2).
contraindication to steroids (2), non-invasive cancer (1). prior
carcinoma (2) or age over 70 years (2).
Surgery at Guy's comprised either a modified radical
mastectomy in patients with tumours greater than 4 cm
diameter or breast conservation therapy for those with
smaller primary tumours. Breast conservation therapy com-
prised tumourectomy, axillary clearance and radiotherapy. At
Withington Hospital patients were treated by total mastec-
tomy or by breast conservation comprising wide excision
followed by radiotherapy.
Patients who gave informed consent were randomised into
the study within 10 days of surgery being performed. They
were followed up at a special adjuvant therapy clinic and
seen every 3 months for 3 years, then 6 monthly for the next
2 years and thereafter annually. Full blood count and
biochemical screen were performed every 6 months together
with a chest radiograph. Mammograms and radioisotopic
bone scans were performed annually. Patients who developed
local relapse had histological confirmation of the diagnosis.
Those with distant relapse had radiological verification.
Statistical methods
Survival and response durations were calculated using the
method of Kaplan and Meier (1958), with significance being
evaluated using the log-rank test (Peto et al.. 1977).
Trial size calculations used when designing the trial em-
ployed the method described by Freedman (1982). It was
initially decided to look for a difference of 10% at 5 years
from a baseline 5 year survival of 70%. This would have
required the randomisation of 793 patients. Guidelines
originally employed for interim analyses were those suggested
by Pocock (1983) with a single interim analysis requiring a
Br. J. Cancer (1994). 70, 729-731 (E) Macmillan Press Ltd.. 1994730 I.S. FENTIMAN et al.
Table I Characteristics of patients treated
tamoxifen and prednisolone (Tam + Pred)
hospitals
by tamoxifen (Tam) or
at Christie and Guy's
Christie Guy's
Tan Tan + Pred Tarn Tam + Pred
Total 51 50 135 134
Ineligible 6 8 7 8
Evaluable 45 42 128 126
Mastectomy 33 31 63 54
Breast conservation 18 19 65 72
Manchester stage
I 5 6 40 41
II 28 26 80 80
III 6 4 5 4
? 6 6 3 1
Histology
Ductal 34 32 95 101
Lobular 5 8 13 12
Mucoid 1 1 1 1
Medullary 1 0 1 1
Mixed 2 1 13 4
Other 2 0 5 7
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Fige I Relapse-free survival of both Guy's and Withington
Hospital patients given either tamoxifen alone or tamoxifen and
prednisolone.
reduction in the P-value necessary for stopping the trial to
0.025.
With the trial giving a negative result, the confidence inter-
vals of the hazard ratio between the two arms were cal-
culated as suggested by Haybittle (1979).
Results
Of the patients who were randomised to receive tamoxifen,
treatment was stopped in five cases because of tiredness,
cramp, weight gain and severe hot flushes. Dosage of tamox-
ifen was reduced to 10 mg daily in one patient who had hot
flushes. In contrast, prednisolone was stopped in 39 patients,
the reasons being weight gain (11), dyspepsia (11), diabetes
(2), patient's wish (3), Cushingoid features (2), bruising (1),
osteoporosis (1), visual problems (2), malaise (1), error (3),
infection (1), and cerebrovascular accident (1). Prednisolone
dosage was reduced in 12 patients because ofweight gain (2),
dyspepsia (5), hypertension (4) and hirsutism (1).
The relapse-free survival of the entire group of patients
from both hospitals, as randomised, is shown in Figure 1. No
significant difference was seen. Similarly, in terms of survival
no statistically significant difference was seen, although there
was a trend towards a worse survival among those given
tamoxifen and prednisolone, as shown in Figure 2.
It is insufficient to report just the P-value from a negative
trial, since this gives no information about the size of the
difference that may still have been missed. By estimating the
hazard ratio, with associated confidence limits, confidence
limits can be produced for the difference at any particular
time (Haybittle, 1979). The hazard ratio for survival was in
fact 1.32 (in favour of tamoxifen alone) with 95% confidence
limits of 0.82-2.13. The survival rate at 5 years in the
tamoxifen alone arm was 73%. Using this as a baseline, and
the two values for the hazard ratio just calculated, gives a
range of 51-77% for the tamoxifen plus prednisolone arm at
5 years. Thus, there is a I in 40 chance of tamoxifen plus
prednisolone being 4% better at 5 years. In a similar way it
can be calculated that there is only a I in 55 chance of
tamoxifen plus prednisolone being 5% better at 5 years, and
only a I in 2,000 chance of tamoxifen plus prednisolone
being 10% better at 5 years.
The purpose of this study was to determine whether pred-
nisolone conveyed additional benefit in women given
adjuvant tamoxifen. Since recruitment to this trial was slow-
ing down, an interim analysis was carried out, at which point
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Figue 2 Overall survival of Guy's and Withington Hospital
cases given either tamoxifen alone or tamoxifen and pred-
nisolone.
the trial was to have been stopped if a difference had
emerged (at a significance level of 0.025) (Pocock, 1983) or if
the results suggested that a survival difference was very
unlikely to be found. By calculating confidence limits on the
hazard ratio, we found that the chances of a survival
difference of even 5% or more in favour of tamoxifen plus
prednisolone were very slight (approximately 1 in 55; see
Results section), and thus the trial had already effectively
excluded the possibility of tamoxifen plus prednisolone show-
ing worthwhile benefit.
Although the pretrial trial size calculations suggested that
800 patients would be required to answer the survival ques-
tion, the actual survival results, with any difference favouring
the tamoxifen alone group, enabled the question to be ans-
wered with considerably fewer patients. This is because the
pretrial calculations must allow for a range of outcomes
within the prescribed limits of a 10% difference in either
direction. With the actual outcomes of a sizeable group of
patients available, considerable additional information is
available on the size and direction of any such difference, and
the results may, as in this case, show some of these outcomes
to be unlikely (the observed trial outcome would be highly
unlikely if there was really a difference of 5% in favour of
tamoxifen plus prednisolone, but still quite possible if the
two treatments give equivalent results, P = 0.26).
These data are consistent with those of a previously pub-
lished small trial of the similar treatment arms (DiMartino et
al., 1991). A series of 169 women, all treated by mastectomy,
were randomised to receive either tamoxifen 40 mg daily or
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tamoxifen and prednisolone 7.5 mg daily. After a median
follow-up of 26 months there were no significant differences
in terms of either relapse-free or overall survival. Another
negative trial has been reported in which tamoxifen and
placebo was compared with tamoxifen and prednisolone in
women with metastatic breast cancer (Ingle et al., 1991).
There was no significant association between treatment and
outcome on covariate analyses. Similarly. the Ludwig group
found no benefit from adding prednisone to adjuvant
chemotherapy comprising cyclophosphamide, methotrexate
and fluorouracil (Goldhirsch et al.. 1986).
Of further concern, there were significantly more side-
effects among those women who received additional pred-
nisolone, particularly weight gain, dyspepsia and fluid reten-
tion. A previous study on patients in this trial demonstrated
that tamoxifen protects against potential steroid-induced
bone loss. with no significant differences in bone mineral
content of those given tamoxifen or tamoxifen and pred-
nisolone after a minimum follow-up of 2 years (Fentiman et
al.. 1992).
Thus, although tamoxifen is of proven benefit in an
adjuvant role for post-menopausal women at risk of relapse
of breast cancer, the results of this study suggest that this
cannot be amplified by additional prednisolone.
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